Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Innovent Biologics Inc (1801.HK)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (HK$) Price Target (HK$) Rating
2020-12-25NaN-No Rating
2021-01-1393.15112.80Buy
2021-03-0870.75132.90Buy
2021-03-3078.20134.40Buy
2021-08-2661.90121.20Buy
2022-01-2540.9065.00Buy
2022-02-1131.6060.00Buy
2022-04-0629.5543.00Buy
2022-06-1426.5039.30Buy
2022-08-0535.8042.00Buy
2023-03-0140.5552.10Buy
2023-04-2837.4548.10Buy
2023-08-2434.6551.20Buy
2023-10-3047.0555.80Buy
2024-03-2138.1057.70Buy

Disclosures

  • UBS Securities Hong Kong Limited is a market maker in the Hong Kong-listed securities of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.